Medical Condition News

RSS

Nearly 50% of essential services provided for cancer treatment not reimbursed by Medicare

A comprehensive study of the components of the delivery of modern-day cancer care in community oncology practices revealed that Medicare covers only 56% of the actual costs of administering chemotherapy and providing related infusion room services to seniors with cancer. The remaining costs -- for essential services provided such as treatment planning, care coordination, and follow-up care planning -- are not reimbursed by Medicare, causing many oncology practices to struggle to continue to provide care under the Medicare program.

5 Feb 2010

Personalized risk assessment tools can help improve smoking cessation

Giving smokers information about their own individual risk of serious illness helps motivate them to quit smoking, according to a paper published in the current issue of Postgraduate Medical Journal.

5 Feb 2010

Study suggests molecules and pathways in mood regulation and circadian rhythms are intertwined

Scientists at Emory University School of Medicine have discovered unexpected properties for a precursor to melatonin, the hormone that regulates sleep cycles.

5 Feb 2010

Hope for back pain: Minimally invasive facet arthrodesis and spinal cord stimulation

Results from the first prospective study of minimally invasive facet arthrodesis and long-term data on spinal cord stimulation demonstrate the viability of these options to achieve pain relief in patients with various back pain conditions. The studies were presented today at the American Academy of Pain Medicine's 26th Annual Meeting in San Antonio, TX.

5 Feb 2010

Pazopanib drug slows the progression of RCC in patients by 54%

The drug pazopanib (Votrient) slowed the progression of advanced renal cell carcinoma (RCC), a form of kidney cancer, in patients by 54% percent, according to a new study published in the Journal of Clinical Oncology.

5 Feb 2010

HSS supports Arthritis Foundation's educational campaign for osteoarthritis

Hospital for Special Surgery, (HSS), a world leader in orthopedics and rheumatology, today announced its support of the Arthritis Foundation and Ad Council newly launched campaign, "Moving is the Best Medicine," to raise awareness of osteoarthritis, increase public health education and support breakthrough research.

5 Feb 2010

Spinal muscular atrophy screening, not cost effective

In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting -, in Chicago, researchers will unveil findings that show that it is not cost effective to screen for spinal muscular atrophy.

5 Feb 2010

Patients with mild gallstone pancreatitis can be operated within 48 hours of admission

Patients with mild gallstone pancreatitis usually stay in the hospital for several days, waiting for the symptoms to subside, before undergoing surgery to remedy the condition. A new study from researchers at Los Angeles Biomedical Research Institute (LA BioMed) indicates patients may no longer have to wait so long for surgery and could leave the hospital sooner.

5 Feb 2010

Vanderbilt Heart and Vascular Institute offers new blood test to predict heart disease

Just in time for American Heart Month, Vanderbilt Heart and Vascular Institute is offering a new blood test that can predict if a patient is at high risk for heart disease. Vanderbilt is among the first institutions in the country, and the only one in Tennessee, to offer this test.

5 Feb 2010

Aradigm's first U.S. sale of SUMAVEL DosePro needle-free delivery system triggers $4M milestone payment

Aradigm Corporation announced today that it received the $4 million milestone payment from Zogenix, Inc. (“Zogenix”) based upon the first commercial sale in the U.S. of SUMAVEL* DosePro* (sumatriptan injection) needle-free delivery system. The Company will receive quarterly royalty payments on all SUMAVEL DosePro sales. In 2006, the Company sold all assets related to the Intraject* needle-free injector technology (now rebranded as DosePro) to Zogenix in exchange for milestone and royalty payments.

5 Feb 2010

San Antonio Methodist Hospital upgrades to Leksell Gamma Knife Perfexion system

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that it has entered into a contract to supply a Leksell Gamma Knife® PerfexionTM system to Methodist Hospital in San Antonio, Texas. This new Perfexion system, the eighth placed by AMS to date, will replace an existing Gamma Knife supplied by AMS and is expected to begin treating patients later this year.

5 Feb 2010

BioMarin announces update on BMN 110 Phase I/II trial for Morquio A Syndrome

BioMarin Pharmaceutical Inc. today announced an update on the Phase I/II trial for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. Preliminary clinical data from the first 24 weeks of the study (12 weeks at 0.1mg/kg and 12 weeks at 1.0 mg/kg) have been evaluated, and BioMarin plans to announce top-line results for the full 36-week study after completion of dosing at 2.0 mg/kg in the second quarter of 2010.

5 Feb 2010

LDDI releases biomonitoring report on environmental neurotoxins in health affected community

The Learning and Developmental Disabilities Initiative (LDDI) today released the first-ever biomonitoring report identifying toxic chemical pollution in people from the learning and developmental disability community.

5 Feb 2010

$AAOS issues new clinical practice guidelines for treating distal radius fractures$

AAOS issues new clinical practice guidelines for treating distal radius fractures

The American Academy of Orthopaedic Surgeons (AAOS) recently approved and released an evidence-based clinical practice guideline on the Treatment of Distal Radius Fractures.

5 Feb 2010

Bioheart initiates REGEN Phase I Clinical Trial for testing genetically modified MyoCell in CHF patients

Bioheart, Inc., announced today that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Bioheart’s MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells,that are grown from a patient’s own muscle. MyoCell® has been tested successfully on patients in four clinical trials.

5 Feb 2010

Use of laparoscopic hepatectomy in treating HCC patients achieves complete resection

Conventional hepatectomy is an effective way to treat hepatocellular carcinoma (HCC). However, it is invasive and stressful. Laparoscopic surgery, a kind of minimally invasive surgery, has recently gained considerable advances.

5 Feb 2010

WORLD Symposium: Protalix Biotherapeutics to present data on taliglucerase alfa Phase III Gaucher disease trial

Protalix Biotherapeutics, Inc. today announced that data from its pivotal Phase III trial of taliglucerase alfa in patients with Gaucher disease will be presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010, February 10-12, 2010 in Miami, Florida.

5 Feb 2010

Scientists discover new technique to destroy individual diseased cells

Using lasers and nanoparticles, scientists at Rice University have discovered a new technique for singling out individual diseased cells and destroying them with tiny explosions.

5 Feb 2010

St. Jude Medical receives European approval for Fortify ST ICD and Unify CRT-D defibrillators

St. Jude Medical, Inc. today announced European CE Mark approval and first implants of its Fortify™ and Fortify ST implantable cardioverter defibrillators (ICD) and Unify™ cardiac resynchronization therapy defibrillator (CRT-D). The devices will be fully launched in Europe later this spring, and U.S. versions of the Fortify ICD and Unify CRT-D are expected to be launched later this year. The reduced size of these new devices compared to those of previous generations creates the smallest available device footprint in the industry.

5 Feb 2010

Pfizer, DxS sign agreement to develop a diagnostic test kit for CDX-110 to treat patients with GBM

Pfizer Inc. and DxS (a wholly owned subsidiary of QIAGEN N.V.) today announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM).

5 Feb 2010

Medical Condition News

Nearly 50% of essential services provided for cancer treatment not reimbursed by Medicare

Personalized risk assessment tools can help improve smoking cessation

Study suggests molecules and pathways in mood regulation and circadian rhythms are intertwined

Hope for back pain: Minimally invasive facet arthrodesis and spinal cord stimulation

Pazopanib drug slows the progression of RCC in patients by 54%

HSS supports Arthritis Foundation's educational campaign for osteoarthritis

Spinal muscular atrophy screening, not cost effective

Patients with mild gallstone pancreatitis can be operated within 48 hours of admission

Vanderbilt Heart and Vascular Institute offers new blood test to predict heart disease

Aradigm's first U.S. sale of SUMAVEL DosePro needle-free delivery system triggers $4M milestone payment

San Antonio Methodist Hospital upgrades to Leksell Gamma Knife Perfexion system

BioMarin announces update on BMN 110 Phase I/II trial for Morquio A Syndrome

LDDI releases biomonitoring report on environmental neurotoxins in health affected community

AAOS issues new clinical practice guidelines for treating distal radius fractures

Bioheart initiates REGEN Phase I Clinical Trial for testing genetically modified MyoCell in CHF patients

Use of laparoscopic hepatectomy in treating HCC patients achieves complete resection

WORLD Symposium: Protalix Biotherapeutics to present data on taliglucerase alfa Phase III Gaucher disease trial

Scientists discover new technique to destroy individual diseased cells

St. Jude Medical receives European approval for Fortify ST ICD and Unify CRT-D defibrillators

Pfizer, DxS sign agreement to develop a diagnostic test kit for CDX-110 to treat patients with GBM

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News